MMRF Molecular Profiling Protocol

Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02884102

Enrollment

1000

Registered

2016-08-30

Start date

2015-06-30

Completion date

2026-06-30

Last updated

2025-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma, Plasma Malignancy

Keywords

genetic sequencing, relapsed

Brief summary

This protocol is now being used as screening for the MyDRUG study

Detailed description

Here we propose an integrative sequencing approach utilizing a 1500 gene exome comparative analysis between multiple myeloma or related plasma cell malignancies and normal cells coupled to capture transcriptome sequencing to provide a nearly comprehensive landscape of the genetic alterations for the purpose of identifying informative and/or actionable mutations in patients with multiple myeloma and plasma cell malignancies. The approach will enable the detection of point mutations, insertions/deletions, gene fusions and rearrangements, amplifications/deletions, and outlier expressed genes among other classes of alterations.

Interventions

GENETICgenetic sequencing

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients must have a diagnosis of multiple myeloma or related malignancy 2. Patients are undergoing standard of care bone marrow aspirates 3. Patients (male or female) from any race or ethnicity must be at least 18 years of age at the time of registration. 4. Procedure-specific signed informed consent form prior to initiation of any study-related procedures.

Exclusion criteria

1. It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo a bone marrow aspirate. 2. Patients who are incarcerated are not eligible to participate. 3. Women who are pregnant 4. Patients who have had another malignancy within the last five (5) years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix) where there is a possibility to contaminate the bone marrow aspirate.

Design outcomes

Primary

Measure	Time frame
actionable mutations report	10-14 days

Secondary

Measure	Time frame
Survival Rates	Overall survival
Disease Recurrence	Time to Progression

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026